Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” second-quarter ...

Greenhaven Road Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the ...

Cellebrite DI ( ($CLBT) ) just unveiled an announcement. On August 15, 2025, Cellebrite DI Ltd. announced its upcoming Annual General Meeting of ...

Lake Street analyst Eric Martinuzzi lowered the firm’s price target on Cellebrite (CLBT) to $22 from $24 and keeps a Buy rating on the shares.

Cellebrite experienced solid growth in Q2 2025, exceeding expectations for sales and earnings. Signs of a rebound are encouraging.

Detailed price information for Cellebrite Di Ltd (CLBT-Q) from The Globe and Mail including charting and trades.

Cellebrite (CLBT) boasts strong growth potential with robust financials, digital forensics leadership, and a durable moat.

Earlier this year, Cellebrite DI Ltd. (NASDAQ:CLBT) underwent an independent review and received a FedRAMP High Ready status. Now, with the US Department of Justice as its sponsor, the company ...

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have received a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com ...

Read today's latest Cellebrite (CLBT) share news from our expert in-house team of financial journalists.